{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:42:13Z","timestamp":1792784533630,"version":"4.5.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"38","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Merck Research Laboratories"},{"DOI":"10.13039\/100004334","name":"Merck & Co., Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.vaccine.2018.01.089","type":"journal-article","created":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T19:13:23Z","timestamp":1535051603000},"page":"5788-5795","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["A double-blind, randomized, controlled, multi-center safety and immunogenicity study of a refrigerator-stable formulation of VARIVAX\u00ae"],"prefix":"10.1016","volume":"37","author":[{"given":"Keith S.","family":"Reisinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgardo A.","family":"Malacaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron J.","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie L.","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon E.","family":"Stek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Kuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.01.089_b0005","series-title":"Fundamental Immunology","author":"Paul","year":"2013"},{"key":"10.1016\/j.vaccine.2018.01.089_b0010","unstructured":"Merck internal data."},{"key":"10.1016\/j.vaccine.2018.01.089_b0015","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0166-0934(86)90048-0","article-title":"Purification of individual varicella-zoster virus (VZV) glycoproteins gpI, gpII, and gpIII and their use in ELISA for detection of VZV glycoprotein-specific antibodies","volume":"14","author":"Keller","year":"1986","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2018.01.089_b0020","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/jmv.1890320310","article-title":"Sensitive enzyme-linked immunosorbent assay for antibody to varicella-zoster virus using purified VZV glycoprotein antigen","volume":"32","author":"Wasmuth","year":"1990","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2018.01.089_b0025","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0264-410X(91)90266-9","article-title":"Antibody assays suitable for assessing immune responses to live varicella vaccine","volume":"9","author":"Provost","year":"1991","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.089_b0030","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/infdis\/149.5.810","article-title":"Epidemiological standardization of a test for susceptibility to mumps","volume":"149","author":"Shehab","year":"1984","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.01.089_b0035","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/00006454-199608000-00010","article-title":"Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years","volume":"15","author":"Johnson","year":"1996","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.01.089_b0040","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/sim.4780091208","article-title":"Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk","volume":"9","author":"Farrington","year":"1990","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2018.01.089_b0045","unstructured":"VARIVAX package insert. Kenilworth, NJ: Merck & Co., Inc.; 2017. Available at: http:\/\/www.merck.com\/product\/usa\/pi_circulars\/v\/varivax\/varivax_pi.pd. [accessed October 19, 2017]."},{"issue":"6","key":"10.1016\/j.vaccine.2018.01.089_b0050","doi-asserted-by":"crossref","first-page":"e1299","DOI":"10.1542\/peds.2006-2283","article-title":"Comparison of the safety and immunogenicity of a refrigerator-stable versus a frozen formulation of ProQuad (measles, mumps, rubella, and varicella virus vaccine live)","volume":"119","author":"Bernstein","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2018.01.089_b0055","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/bmj.285.6341.531","article-title":"Further field testing of the more heat-stable measles vaccine in Cameroon","volume":"285","author":"Heymann","year":"1982","journal-title":"Br Med J (Clin Res Ed)."},{"key":"10.1016\/j.vaccine.2018.01.089_b0060","series-title":"Thermostability of vaccines: global programme for vaccines and immunization (GPV)","author":"Galazka","year":"1998"},{"key":"10.1016\/j.vaccine.2018.01.089_b0065","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1542\/peds.2007-2013","article-title":"Refrigerator-stable and frozen formulation of ProQuad: In reply","volume":"120","author":"Bernstein","year":"2007","journal-title":"Pediatrics"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18301622?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18301622?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,21]],"date-time":"2019-09-21T14:39:12Z","timestamp":1569076752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18301622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":13,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0264410X18301622"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.01.089","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A double-blind, randomized, controlled, multi-center safety and immunogenicity study of a refrigerator-stable formulation of VARIVAX\u00ae","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.01.089","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}